2-(3-fluoro-4-methoxyphenyl)-6-methoxybenzo[b]thiophene | 414861-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 2-(3-fluoro-4-methoxyphenyl)-6-methoxybenzo[b]thiophene
• 英文别名: 2-(3-Fluoro-4-methoxyphenyl)-6-methoxy-1-benzothiophene
• CAS: 414861-47-5
• 化学式: C₁₆H₁₃FO₂S
• 分子量: 288.342
• InChiKey: DYVSLOHCHCVGGB-UHFFFAOYSA-N

物化性质

• 沸点：
  441.7±45.0 °C(Predicted)
• 密度：
  1.250±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(3-fluoro-4-methoxyphenyl)-6-methoxybenzo[b]thiophene 在 三溴化硼 作用下， 生成 2-(3-fluor-4-hydroxyphenyl)benzo[b]thiophene-6-ol
  参考文献：
  名称：

  Toward Selective ERβ Agonists for Central Nervous System Disorders:  Synthesis and Characterization of Aryl Benzthiophenes

  摘要：

  In an effort to identify selective ligands for the estrogen receptor subtype ERbeta, a series of aryl benzthiophenes was synthesized. In a radioligand binding assay and reporter gene assays in HeLa and SH-SY5Y cells, compounds were characterized as ERbeta-selective agonists. By targeting ER in the brain, these compounds could lead to drugs able to separate the beneficial effects of estrogens on mood, learning, and memory from side effects such as the stimulation of endometrial and breast cancer.

  DOI：

  10.1021/jm015577l
• 作为产物：
  描述：

  6-甲氧基苯并噻吩 在 四(三苯基膦)钯 、 正丁基锂 、 sodium carbonate 作用下， 生成 2-(3-fluoro-4-methoxyphenyl)-6-methoxybenzo[b]thiophene
  参考文献：
  名称：

  Toward Selective ERβ Agonists for Central Nervous System Disorders:  Synthesis and Characterization of Aryl Benzthiophenes

  摘要：

  In an effort to identify selective ligands for the estrogen receptor subtype ERbeta, a series of aryl benzthiophenes was synthesized. In a radioligand binding assay and reporter gene assays in HeLa and SH-SY5Y cells, compounds were characterized as ERbeta-selective agonists. By targeting ER in the brain, these compounds could lead to drugs able to separate the beneficial effects of estrogens on mood, learning, and memory from side effects such as the stimulation of endometrial and breast cancer.

  DOI：

  10.1021/jm015577l

文献信息

• COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
  申请人：BURKS Heather Elizabeth

  公开号：US20140235660A1

  公开（公告）日：2014-08-21

  The present invention relates to compounds of formula I: in which n, m, X, Y 1 , R 1 , R 2 , R 3 , R 4 and R 5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.

  本发明涉及式I的化合物： 其中n、m、X、Y1、R1、R2、R3、R4和R5在本发明概要中有定义；能够同时作为雌激素受体的强效拮抗剂和降解剂。本发明还提供了一种制备本发明化合物的方法，包括含有此类化合物的药物制剂以及使用这些化合物和组合物在管理与异常雌激素受体活性相关的疾病或紊乱的方法。
• BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
  申请人：NOVARTIS AG

  公开号：US20170112805A1

  公开（公告）日：2017-04-27

  The present invention relates to compounds of formula I: in which n, m, X, Y 1 , R 1 , R 2 , R 3 , R 4 and R 5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.

  本发明涉及公式I的化合物：其中n，m，X，Y1，R1，R2，R3，R4和R5在发明摘要中定义；能够同时作为雌激素受体的强拮抗剂和降解剂。本发明还提供了制备本发明化合物的方法，包含这些化合物的药物制剂，以及使用这些化合物和组合物在管理与异常雌激素受体活性相关的疾病或紊乱的方法。
• Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
  申请人：NOVARTIS AG

  公开号：US10058534B2

  公开（公告）日：2018-08-28

  The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.

  本发明涉及式 I 的化合物： 其中 n、m、X、Y1、R1、R2、R3、R4 和 R5 在本发明的摘要中定义；能够成为雌激素受体的强效拮抗剂和降解剂。本发明进一步提供了制备本发明化合物的工艺、包含此类化合物的药物制剂以及使用此类化合物和组合物治疗与雌激素受体活性异常有关的疾病或紊乱的方法。
• US8877801B2
  申请人：——

  公开号：US8877801B2

  公开（公告）日：2014-11-04
• US9321746B2
  申请人：——

  公开号：US9321746B2

  公开（公告）日：2016-04-26